Travere Therapeutics, Inc. (TVTX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Travere Therapeutics, Inc. (TVTX) Healthcare & Pipeline Overview

Travere Therapeutics, Inc. is a biopharmaceutical company specializing in rare disease therapies, with a focus on kidney and liver disorders. The company's established product portfolio and pipeline of novel candidates position it within the competitive biotechnology landscape, targeting unmet medical needs.

What Is the Investment Thesis for TVTX?

Travere Therapeutics presents a focused investment opportunity within the rare disease biopharmaceutical sector. Key value drivers include the continued commercial success of its existing product portfolio (Chenodal, Cholbam, and Thiola) and the potential approval and launch of Sparsentan for FSGS and IgAN. Positive Phase III clinical trial results for Sparsentan could serve as a significant catalyst. The company's pipeline, including TVT-058, offers long-term growth potential. However, the company's negative profit margin of -10.2% and the inherent risks associated with clinical trials and regulatory approvals should be considered. The company's beta of 0.87 suggests lower volatility compared to the broader market.

Based on FMP financials and quantitative analysis

TVTX Key Highlights

• Market capitalization of $5.27B reflects investor confidence in Travere's rare disease focus and pipeline potential.
• Gross margin of 94.2% indicates strong pricing power and efficient cost management in its marketed products.
• Sparsentan's Phase III clinical trials for FSGS and IgAN represent significant near-term catalysts for potential revenue growth.
• Collaboration with NIH and patient advocacy groups enhances research and development efforts in identifying novel therapeutics.
• The company's focus on rare diseases provides opportunities for orphan drug designation and market exclusivity.

Who Are TVTX's Competitors?

TVTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TVTX's Key Strengths?

• Established portfolio of marketed products for rare diseases.
• Promising pipeline of novel drug candidates, including Sparsentan and TVT-058.
• Strong relationships with key opinion leaders and patient advocacy groups.
• Experienced management team with expertise in rare disease drug development.

What Are TVTX's Weaknesses?

• Negative profit margin.
• Reliance on a limited number of products for revenue generation.
• High R&D expenses associated with drug development.
• Dependence on successful clinical trial outcomes and regulatory approvals.

What Could Drive TVTX Stock Higher?

• Potential FDA approval decision for Sparsentan in FSGS expected in the near term.
• Potential FDA approval decision for Sparsentan in IgAN expected in the near term.
• Continued commercial growth of Cholbam and Thiola.
• Enrollment and data readouts from TVT-058 Phase I/II clinical trials.

What Are the Key Risks for TVTX?

• Negative return on equity (-26.8%) — the business is not currently generating profit on shareholder capital.
• Unfavorable FDA decisions regarding Sparsentan approval.
• Clinical trial failures for TVT-058 or other pipeline candidates.
• Competition from other companies in the rare disease space.
• Pricing pressures and reimbursement challenges for rare disease therapies.
• Product liability risks associated with pharmaceutical products.

What Are the Growth Opportunities for TVTX?

• Growth opportunity 1: Sparsentan's potential approval and commercialization for FSGS represents a significant growth driver. FSGS is a rare kidney disorder with limited treatment options, creating a substantial unmet need. If approved, Sparsentan could capture a significant share of this market, estimated to be worth several hundred million dollars annually. Regulatory decisions are expected in the near term, with potential launch within the next 12-18 months, providing a clear timeline for revenue generation.
• Growth opportunity 2: Sparsentan's potential approval and commercialization for IgAN represents another significant growth driver. IgAN is a rare kidney disorder with limited treatment options, creating a substantial unmet need. If approved, Sparsentan could capture a significant share of this market, estimated to be worth several hundred million dollars annually. Regulatory decisions are expected in the near term, with potential launch within the next 12-18 months, providing a clear timeline for revenue generation.
• Growth opportunity 3: Expansion of Cholbam's label and market reach represents a steady growth opportunity. Cholbam is approved for bile acid synthesis disorders, but there is potential to expand its use to other related conditions. Increasing awareness among physicians and patients, coupled with strategic marketing efforts, could drive further adoption and revenue growth over the next 3-5 years.
• Growth opportunity 4: Advancement of TVT-058, a novel enzyme replacement therapy for classical homocystinuria, through clinical trials represents a longer-term growth opportunity. If successful, TVT-058 could address a significant unmet need in this rare genetic disorder. Phase I/II trials are currently underway, with potential for pivotal trials and regulatory submissions in the next 3-5 years.
• Growth opportunity 5: Strategic collaborations and acquisitions represent a potential avenue for expanding Travere's pipeline and market presence. Partnering with other companies or acquiring complementary assets could accelerate the development of new therapies and broaden the company's portfolio of rare disease treatments. These opportunities could materialize over the next 2-3 years.

What Opportunities Does TVTX Have?

• Potential approval and commercialization of Sparsentan for FSGS and IgAN.
• Expansion of Cholbam's label and market reach.
• Advancement of TVT-058 through clinical trials.
• Strategic collaborations and acquisitions to expand pipeline and market presence.

What Threats Does TVTX Face?

• Competition from other companies developing therapies for rare diseases.
• Unsuccessful clinical trial outcomes or regulatory setbacks.
• Pricing pressures and reimbursement challenges.
• Product liability claims.

What Are TVTX's Competitive Advantages?

• Orphan drug designation provides market exclusivity for certain products.
• Strong intellectual property protection for key pipeline assets.
• Established relationships with key opinion leaders and patient advocacy groups.
• Specialized expertise in rare disease drug development and commercialization.

What Does TVTX Do?

Travere Therapeutics, Inc., formerly Retrophin, Inc., was founded in 2008 and is headquartered in San Diego, California. The company is dedicated to identifying, developing, and commercializing therapies for rare diseases. Travere's marketed products include Chenodal, used for treating radiolucent gallstones; Cholbam, a cholic acid capsule for bile acid synthesis disorders and peroxisomal disorders; and Thiola and Thiola EC, used in the treatment of homozygous cystinuria. The company's pipeline includes Sparsentan, currently in Phase III clinical trials for focal segmental glomerulosclerosis (FSGS) and immunoglobulin A nephropathy (IgAN), and TVT-058, an enzyme replacement candidate in Phase I/II clinical trials for classical homocystinuria. Travere collaborates with the National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations like CDG Care and Alagille Syndrome Alliance to identify potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. Travere's focus on rare diseases allows it to address unmet medical needs and potentially achieve market exclusivity.

What Products and Services Does TVTX Offer?

• Develop and commercialize therapies for rare diseases.
• Market Chenodal for the treatment of radiolucent gallstones.
• Market Cholbam for the treatment of bile acid synthesis disorders.
• Market Thiola and Thiola EC for the treatment of homozygous cystinuria.
• Develop Sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS) and immunoglobulin A nephropathy (IgAN).
• Develop TVT-058 for the treatment of classical homocystinuria.
• Collaborate with research institutions and patient advocacy organizations to identify new therapeutic targets.

How Does TVTX Make Money?

• Develop and commercialize proprietary pharmaceutical products.
• Generate revenue through direct sales of marketed products.
• Out-license or partner on select programs to expand market reach.
• Invest in research and development to advance pipeline candidates.

What Industry Does TVTX Operate In?

Travere Therapeutics operates within the biotechnology industry, specifically targeting the rare disease market. This segment is characterized by high unmet medical needs, regulatory incentives such as orphan drug designation, and potential for market exclusivity. The competitive landscape includes companies like CELC: Celcuity Inc., CGON: CG Oncology Inc, CNTA: Centessa Pharmaceuticals plc, XENE: Xenon Pharmaceuticals Inc., and LEGN: Legend Biotech Corporation, each focusing on different therapeutic areas or approaches. The rare disease market is experiencing growth driven by increased awareness, improved diagnostics, and advancements in personalized medicine.

Who Are TVTX's Key Customers?

• Patients with rare diseases.
• Physicians who treat rare diseases.
• Hospitals and clinics.
• Specialty pharmacies.

How Travere Therapeutics, Inc. Is Valued

Travere Therapeutics, Inc. carries a market capitalization of $5.27B, placing it in the mid-cap category. Relative to its peer group, TVTX's quantitative score of 36/100 is roughly in line with the peer average of 46/100.

ROE -27%Key Financial Metrics

Return on equity for Travere Therapeutics, Inc. stands at -26.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -3.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.13 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.4%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 4/9Financial Health

Travere Therapeutics, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 4.54 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Travere Therapeutics, Inc. revenue of about $696.0M for fiscal 2026, with EPS near $0.17. The estimate reflects 11 contributing analysts.

TVTX Financials

TVTX Latest News

TVTX Analyst Consensus

TVTX MoonshotScore

Latest Travere Therapeutics, Inc. Analysis

TVTX Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources